Technical Analysis for SZLS - Stagezero Life Sciences Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Centerline Cross | Bearish | 0.00% | |
| Jack-in-the-Box Bearish | Bearish Swing Setup | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | 0.00% | |
| 50 DMA Resistance | Bearish | 0.00% | |
| Expansion Breakdown | Bearish Swing Setup | 0.00% | |
| Volume Surge | Other | 0.00% |
| Alert | Time |
|---|---|
| 5x Volume Pace | 11 days ago |
| 3x Volume Pace | 11 days ago |
| 2x Volume Pace | 11 days ago |
| 1.5x Volume Pace | 11 days ago |
| 5x Volume Pace | 14 days ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2024-05-13
StageZero Life Sciences Inc., formerly GeneNews Ltd, is a Canada-based company focused on developing and commercializing molecular diagnostic tests for early detection of cancer. It has developed Sentinel Principle platform technology, which determines biomarkers from whole blood. In additional, the Company offers ColonSentry product, it is a blood test to determine an individual’s current risk for having colorectal cancer. It is developing cancer testing kit Aristotle, which is a multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood. The Company is also focused on testing Aristotle application on other disease conditions including neurology, gastroenterology, cardiology, and autoimmune disorders.
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Mines Medicine Biotechnology Disease Science Cancer RTT Life Sciences Clinical Medicine Disorders Cancers Cell Biology Neurology Biomarker Cardiology
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Mines Medicine Biotechnology Disease Science Cancer RTT Life Sciences Clinical Medicine Disorders Cancers Cell Biology Neurology Biomarker Cardiology
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.15 |
| 52 Week Low | 0.035 |
| Average Volume | 89,058 |
| 200-Day Moving Average | 0.054 |
| 50-Day Moving Average | 0.044 |
| 20-Day Moving Average | 0.045 |
| 10-Day Moving Average | 0.046 |
| Average True Range | 0.004 |
| RSI (14) | 45.36 |
| ADX | 12.34 |
| +DI | 36.276 |
| -DI | 30.710 |
| Chandelier Exit (Long, 3 ATRs) | 0.044 |
| Chandelier Exit (Short, 3 ATRs) | 0.051 |
| Upper Bollinger Bands | 0.052 |
| Lower Bollinger Band | 0.037 |
| Percent B (%b) | 0.21 |
| BandWidth | 34.607 |
| MACD Line | 0.000 |
| MACD Signal Line | 0.001 |
| MACD Histogram | -0.0008 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.040 | ||||
| Resistance 3 (R3) | 0.040 | 0.040 | 0.040 | ||
| Resistance 2 (R2) | 0.040 | 0.040 | 0.040 | 0.040 | |
| Resistance 1 (R1) | 0.040 | 0.040 | 0.040 | 0.040 | 0.040 |
| Pivot Point | 0.040 | 0.040 | 0.040 | 0.040 | 0.040 |
| Support 1 (S1) | 0.040 | 0.040 | 0.040 | 0.040 | 0.040 |
| Support 2 (S2) | 0.040 | 0.040 | 0.040 | 0.040 | |
| Support 3 (S3) | 0.040 | 0.040 | 0.040 | ||
| Support 4 (S4) | 0.040 |
